77042 “Augmented” High-Dose Infliximab 12.5 mg/kg is Safe and Effective in Hidradenitis Suppurativa
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB8
DOI: 10.1016/j.jaad.2026.04.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Isabell A. Guzchenko und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Guzchenko, I. A., Mitelman, A., Do, H. K., Romanelli, S., Trenholm, I. M., Tan, I. J., & Cohen, S. R. (2026). 77042 “Augmented” High-Dose Infliximab 12.5 mg/kg is Safe and Effective in Hidradenitis Suppurativa. Journal of the American Academy of Dermatology, 95(1), AB8. https://doi.org/10.1016/j.jaad.2026.04.048
Vancouver
Guzchenko IA, Mitelman A, Do HK, Romanelli S, Trenholm IM, Tan IJ, et al. 77042 “Augmented” High-Dose Infliximab 12.5 mg/kg is Safe and Effective in Hidradenitis Suppurativa. Journal of the American Academy of Dermatology. 2026;95(1):AB8. doi:10.1016/j.jaad.2026.04.048
BibTeX
@article{Guzchenko2026,
author = {Guzchenko, Isabell A. and Mitelman, Alexis and Do, Huongly K. and Romanelli, Sarah and Trenholm, Isabel M. and Tan, Isabella J. and Cohen, Steven R.},
title = {77042 “Augmented” High-Dose Infliximab 12.5 mg/kg is Safe and Effective in Hidradenitis Suppurativa},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB8},
doi = {10.1016/j.jaad.2026.04.048}
}
EUVIMED